- The stock price of Pfizer Inc. (NYSE: PFE) increased by over 1% during intraday trading today. This is why it happened.
The stock price of Pfizer Inc. (NYSE: PFE) increased by over 1% during intraday trading today. Investors are responding positively to Pfizer saying that its COVID vaccine is safe and effective for kids between the ages of 5 and 11.
Specifically, a smaller dose of the Pfizer and BioNTech Covid-19 vaccine dose generated a robust immune response as part of a clinical trial of kids ages 5 to 11. This is a big deal for parents who are awaiting news about being able to get their children vaccinated during the new school year as the delta variant is still spreading quickly across America. According to the American Academy of Pediatrics, there were 243,000 new Covid infections among children for the week ended September 9.
Pfizer said that its data — which included over 2,200 children — is being submitted to the Food and Drug Administration (FDA) and other health regulators as soon as possible. It is likely going to be submitted by the end of this month. This could ensure that the shots could become available for those in that age range could become available by Halloween (October 31).
Pfizer tested a two-dose regiment of 10 micrograms — which is about a third of the dosage used for teenagers and adults. This dosage was administered 3 weeks apart. And during the trial, those who participated in the trial produced an immense response and it was well-tolered. The side effects were comparable to those in a study of people ages between 16 and 25.
“We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children,” said Pfizer CEO Albert Bourla in a statement.
As of the end of October, Pfizer is expecting to release clinical trial data on how well the Covid vaccine works for children as young as 6 months to 5 years old.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.